Vivendi in last ditch effort to avert EU fine for closing Lagardere deal too soon


The logo of French media giant Vivendi is seen in Paris, France, January 14, 2025. REUTERS/Gonzalo Fuentes

BRUSSELS, Dec 10 (Reuters) - French media conglomerate Vivendi made a last-ditch effort on Wednesday to stave off a potential EU antitrust fine, following charges it closed its acquisition of publisher Lagardere before receiving regulatory approval.

Vivendi, represented by more than a dozen lawyers, made its case to senior competition officials and lawyers at the European Commission as well as French antitrust officials at a day-long closed hearing. Lagardere's lawyers were also present.

All the participants declined to comment.

The Commission, which acts as the EU competition watchdog, in its July charge sheet said Vivendi breached the standstill obligation set out in the bloc's merger rules.

The company, which has rejected the charges, risks a fine of as much as 10% of its global annual revenue if found guilty of breaking EU rules.

The Commission, which takes a tough line against procedural violations and has handed out stiff fines in recent years, is set to issue its decision next year.

It cleared the Lagardere deal prior to opening the investigation.

(Reporting by Foo Yun Chee; Editing by Kirsten Donovan)

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Tech News

Tesla's Cybercab, Optimus output to start 'agonizingly slow', ramp up later, Musk says
Airwallex buys South Korea's Paynuri after fundraising at $8 billion valuation
Wipro CEO sees growing demand for India's IT services from AI
Brazil issues recommendation for X to tackle fake sexualized content through Grok
Netflix slightly beats revenue estimates, shares slide amid bidding war for Warner Bros
OpenAI rolls out age prediction on ChatGPT
FTC appeals ruling in Meta antitrust case over Instagram, WhatsApp deals
Netflix will now pay all cash for Warner Bros to keep Paramount at bay
AI startup Humans& raises $480 million at $4.5 billion valuation in seed round
Roche's Genentech more than doubles investment in North Carolina facility to about $2 billion

Others Also Read